Multimeric ACE2-IgM fusions as broadly active antivirals that potently neutralize SARS-CoV-2 variants
Open Access
- 12 November 2022
- journal article
- research article
- Published by Springer Nature in Communications Biology
- Vol. 5 (1) , 1-7
Abstract
Coronavirus infections are a world-wide threat to human health. A promising strategy to develop a broadly active antiviral is the use of fusion proteins consisting of an antibody IgG Fc region and a human ACE2 domain to which the viral spike proteins bind. Here we create antiviral fusion proteins based on IgM scaffolds. The hexameric ACE2-IgM-Fc fusions can be efficiently produced in mammalian cells and they neutralize the infectious virus with picomolar affinity thus surpassing monomeric ACE2-IgM-Fc by up to 96-fold in potency. In addition, the ACE2-IgM fusion shows increased neutralization efficiency for the highly infectious SARS-CoV-2 omicron variant in comparison to prototypic SARS-CoV-2. Taken together, these multimeric IgM fusions proteins are a powerful weapon to fight coronavirus infections.Keywords
This publication has 27 references indexed in Scilit:
- Human recombinant soluble ACE2 in severe COVID-19The Lancet Respiratory Medicine, 2020
- Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-IgNature Communications, 2020
- U1 snRNP regulates cancer cell migration and invasion in vitroNature Communications, 2020
- A peptide extension dictates IgM assemblyProceedings of the National Academy of Sciences, 2017
- Biophysical properties of the clinical-stage antibody landscapeProceedings of the National Academy of Sciences, 2017
- Viral Concentration Determination Through Plaque Assays: Using Traditional and Novel Overlay SystemsJournal of Visualized Experiments, 2014
- High-resolution structures of the IgM Fc domains reveal principles of its hexamer formationProceedings of the National Academy of Sciences, 2013
- Fc‐fusion proteins: new developments and future perspectivesEMBO Molecular Medicine, 2012
- Recombinant Human Hexamer-Dominant IgM Monoclonal Antibody to Ganglioside GM3 for Treatment of MelanomaClinical Cancer Research, 2007
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003